C-X-C Chemokine Receptor Type 4 (CXCR4) and Programmed Death-Ligand 1 (PD-L1) Expression are Prognostic Biomarkers for Papillary Thyroid Carcinoma

被引:0
|
作者
Ding, Ting [1 ]
Song, Qian [1 ]
Xu, Yanjun [2 ]
Liu, Qiya [3 ]
机构
[1] Huanggang Cent Hosp, Dept Endocrinol, Huanggang City 438021, Hubei, Peoples R China
[2] Zhejiang Univ Tradit Chinese Med, Dept Special Inspect Sect, Affiliated Hosp 3, Hangzhou 310014, Zhejiang, Peoples R China
[3] Sha He Hosp Chang Ping Dist Beijing, Dept Gen Med, Beijing 100005, Peoples R China
关键词
CXCR4; PD-L1; Papillary Thyroid Carcinoma; Survival Analysis; CANCER; SURVIVAL; NIVOLUMAB; ANTITUMOR; PATHWAY;
D O I
10.1166/jbt.2022.2987
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Chemokines and immunomodulatory factors involve in tumor development. Papillary thyroid carcinoma (PTC) is considered to start from dendritic cell infiltration and then produce immunomodulatory factors. In this study, CXCR4 and PD-L1 biomarkers were used to explore their prognostic role in PTC survival. Confocal microscopy detected the transfection efficiency in tumor cells. 42 PTC patients and thyroiditis patients (control) were enrolled to measure the expressions of CXCR4 and PD-L1. Multi-factor analysis analyzed the effect of combined CXCR4 and PD-L1 expression on ROC. The two groups had no differences in the baseline characteristics. CTXCR4 and PD-L1 level in PTC patients was significantly higher than control. CXCR4 was lowly expressed in thyroid cancer tissue and PD-L1 was highly expressed in serological samples. Compared with single measurement, the combined detection of CXCR4 and PD-L1 showed more ROC area. In conclusion, reduced CXCR4 and increased PD-L1 levelis found in thyroid cancer and their level might be used IP: 182.75.148.10 On: Thu, 20 Jan 2022 10:55:44 as predictive markers for PTtoCopyright:improve thAmeriancurative Scintificeffect. Publishers
引用
收藏
页码:953 / 957
页数:5
相关论文
共 50 条
  • [31] PD-1, CTLA4, PD-L1 and PD-L2 DNA methylation in papillary thyroid carcinoma
    de Vos, Luka
    Dietrich, Joern
    Strieth, Sebastian
    Bootz, Friedrich
    Dietrich, Dimo
    Franzen, Alina
    IMMUNOTHERAPY, 2020, 12 (12) : 903 - 920
  • [32] Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
    Hanna, Glenn J.
    Kacew, Alec J.
    Tanguturi, Anusha R.
    Grote, Hans J.
    Vergara, Victoria
    Brunkhorst, Beatrice
    Rabinowits, Guilherme
    Thakuria, Manisha
    LeBoeuf, Nicole R.
    Ihling, Christian
    DeCaprio, James A.
    Lorch, Jochen H.
    FRONTIERS IN MEDICINE, 2020, 7
  • [33] Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma
    Semra Paydas
    Emine Bağır
    Gulsah Seydaoglu
    Vehbi Ercolak
    Melek Ergin
    Annals of Hematology, 2015, 94 : 1545 - 1552
  • [34] Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
    Abbas, M.
    Steffens, S.
    Bellut, M.
    Eggers, H.
    Grosshennig, A.
    Becker, J. U.
    Wegener, G.
    Schrader, A. J.
    Gruenwald, V.
    Ivanyi, P.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [35] The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer
    Choi, Yoon Ji
    Chang, Won Jin
    Shin, Sang Won
    Park, Kyong Hwa
    Kim, Seung Tae
    Kim, Yeul Hong
    ONCOTARGETS AND THERAPY, 2016, 9 : 3307 - 3312
  • [36] Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis
    Xu, Feng
    Xu, Lingling
    Wang, Qian
    An, Guangyu
    Feng, Guosheng
    Liu, Fuquan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 14595 - 14603
  • [37] Expression Analysis of Programmed Death-Ligand (PD-L) 1 in Large Cell Neuroendocrine Carcinoma
    Sakaue, T.
    Nakaoka, H.
    Okazaki, M.
    Shigematsu, H.
    Izutani, H.
    Sano, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S971 - S971
  • [38] The pathological role of C-X-C chemokine receptor type 4 (CXCR4) in colorectal cancer (CRC) progression; special focus on molecular mechanisms and possible therapeutics
    Hjazi, Ahmed
    Nasir, Faryal
    Noor, Rabia
    Alsalamy, Ali
    Zabibah, Rahman S.
    Romero-Parra, Rosario Mireya
    Ullah, Muhammad Ikram
    Mustafa, Yasser Fakri
    Qasim, Maytham T.
    Akram, Shaik Vaseem
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 248
  • [39] Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance
    Mondal, Santosh Kumar
    Bhattacharya, Saptarshi
    Sarkar, Aditya Prasad
    Saha, Rama
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S81 - S86
  • [40] Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma
    Alaghehbandan, Reza
    Stehlik, Jan
    Trpkov, Kiril
    Magi-Galluzzi, Cristina
    Mundo, Enric Condom
    Foix, Maria Pane
    Berney, Daniel
    Sibony, Mathilde
    Suster, Saul
    Agaimy, Abbas
    Montiel, Delia Perez
    Pivovarcikova, Kristyna
    Michalova, Kvetoslava
    Daum, Ondrej
    Ondic, Ondrej
    Rotterova, Pavla
    Dusek, Martin
    Hora, Milan
    Michal, Michal
    Hes, Ondrej
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2017, 29 : 17 - 22